Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 9;123(4):402–414. doi: 10.1055/a-1981-1763

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ )

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.

PMC Copyright notice

Fig. 1 — Plasma concentrations of rivaroxaban (A) and apixaban (B) in Adage patients as a function of time since the last oral intake. ( A ) Patients receiving rivaroxaban 10, 15, or 20 mg o.d. are represented with yellow, red, and grey circles, respectively (noteworthy, 10 mg off-labeled in AF). In order to facilitate interpretation, we represented the geometric mean C _max and C _min and the 5th–95th percentiles, i.e ., 229 ng/mL (5th–95th: 178–313) and 57 ng/mL (5th–95th: 18–136), as reported in ROCKET-AF patients (median age: 73 years) receiving 15 mg according to Girgis et al ²¹ with solid and dashed lines, respectively. ( B ) Patients receiving apixaban 2.5 or 5 mg b.i.d. are represented with blue and grey circles, respectively. We represented the median C _max and C _min and 5th–95th percentiles, i.e. , 123 ng/mL (5th–95th: 69–221) and 79 ng/mL (5th–95th: 34–162), as reported in patients receiving apixaban 2.5 mg b.i.d. in ARISTOTLE trial ¹¹ (median age: 70 years), with solid and dashed lines, respectively. AF, atrial fibrillation; b.i.d., twice daily; o.d., once daily.